申请人:Metabasis Therapeutics, Inc.
公开号:EP2786985A2
公开(公告)日:2014-10-08
The present invention provides for novel compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as their use in methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistence and hyperglycemia.
本发明提供了具有胰高血糖素受体拮抗剂或反向激动剂活性的新型式 I 化合物及其药学上可接受的盐和共晶体。本发明进一步提供了包含这些化合物的药物组合物,以及它们在治疗、预防、推迟发病时间或降低疾病或病情发展或恶化风险的方法中的用途,这些疾病或病情适用于一种或多种胰高血糖素受体拮抗剂,包括 I 型和 II 型糖尿病、胰岛素抵抗和高血糖症。